Ceribell Revenue and Competitors

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. We have developed a highly innovative electroencephalography (EEG) device, which will make the diagnosis of neurological patients drastically more efficient. Our device has gained FDA clearance recently and high interest from the market. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizure. We've created and validated an FDA cleared instant EEG system that does not require an EEG tech for a long setup or waiting for a specialist to interpret the initial results. The Ceribell system can be set up by any user in less than 6 minutes and offers a proprietary brain stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizure can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that need EEG for detection, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.